Obesity Drug Talks Reach Defining Moment as Lilly and Novo Near Trump Administration Pricing Deal
In a major policy moment, Lilly and Novo Nordisk are in active talks with U.S. officials to cap obesity drug prices, aligning political pressure with market strategy.